Patent AU-2020340881-A1 (AU)
Title: Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
Inventor: BABB ROBERT
IPC: A61K39/395
Filed: 2020-06-25
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) 
(19) World Intellectual Property 
(1) Organization11111111111111111111111I1111111111111ii111liiili 
International Bureau (10) International Publication Number 
(43) International Publication Date W O 2021/045836 Al 
11 March 2021 (11.03.2021) W IPO I PCT 
(51) InternationalPatent Classification: York 10591 (US). BAUM, Alina; c/o Regeneron Phar
A61K39/215(2006.01) A61K45/06 (2006.01) maceuticals, Inc., 777 Old Saw Mill River Road, Tarry
A61K39/395 (2006.01) C07K16/10 (2006.01) town, New York 10591 (US). CHEN, Gang; c/o Regen
(21) International Application Number: eron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, 
PCT/US2020/039707 Tarrytown, New York 10591 (US). GERSON, Cindy; c/ 
o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Riv
(22) International Filing Date: er Road, Tarrytown, New York 10591 (US). HANSEN, 
25 June 2020 (25.06.2020) Johanna; c/o Regeneron Pharmaceuticals, Inc., 777 Old 
Saw Mill River Road, Tarrytown, New York 10591 (US).  
(25)FilingLanguage: English HUANG, Tammy; c/o Regeneron Pharmaceuticals, Inc., 
(26) Publication Language: English 777 Old Saw Mill RiverRoad, Tarrytown, New York 10591 
(30)PriorityData: (US). KYRATSOUS, Christos; c/o Regeneron 
Pharma
300) ,312 P r Data: 2020(02.0ceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, 
63/004,312 02April2020(02.04.2020) US New York 10591 (US). LEE,Wen-Yi; c/o RegeneronPhar
63/014,687 23 April 2020 (23.04.2020) US maceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, 
63/025,949 15 May 2020 (15.05.2020) US New York 10591 (US). MALBEC, Marine; c/o Regen
63/034,865 04 June 2020 (04.06.2020) US eron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, 
(71) Applicant: REGENERON PHARMACEUTICALS, Tarrytown, New York 10591 (US). MURPHY, Andrew; 
INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill 
New York 10591 (US). River Road, Tarrytown, New York 10591 (US). OLSON, 
William; c/o Regeneron Pharmaceuticals, Inc., 777 Old 
(72)Inventors:BABB,Robert;doRegeneronPharmaceuti- Saw Mill River Road, Tarrytown, New York 10591 (US).  
cals, Inc., 777 Old Saw Mill River Road, Tarrytown, New STAHL, Neil; c/o Regeneron Pharmaceuticals, Inc., 777 
(54) Title: ANTI-SARS-COV-2-SPIKE GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS 
mAb10933 LC m 0 - HC 
- mAbl0987 - LC 
mAb10987 - HC 
FIG.13A 
14 
(57)Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to acoronavirus 
C spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).  
OThe present disclosure provides neutralizing human antigen-binding proteins that specifically bind to SARS-CoV-2-S, for example, 
antibodies or antigen-binding fragments thereof.
W O 202 1/04583 6 A 1 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Old Saw Mill River Road, Tarrytown, New York 10591 
(US). YANCOPOULOS, George, D.; c/oRegeneronPhar
maceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, 
New York 10591 (US).  
(74) Agent: TERMES, Lance, A.; Schwabe, Williamson & 
Wyatt PC, 1211 SW 5th Ave., Suite 1900, Portland, Oregon 
97204 (US).  
(81) Designated States (unless otherwise indicated, for every 
kind of national protection available): AE, AG, AL, AM, 
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, 
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.  
(84) Designated States (unless otherwise indicated, for every 
kind of regional protection available): ARIPO (BW, GH, 
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 
EE, ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 
KM, ML, MR, NE, SN, TD, TG).  
Declarations under Rule 4.17: 
- as to applicant's entitlement to apply for and be granted a 
patent (Rule 4.17(ii)) 
- as to the applicant's entitlement to claim the priority of the 
earlier application (Rule 4.17(iii)) 
Published: 
- with international search report (Art. 21(3)) 
- before the expiration of the time limit for amending the 
claims and to be republished in the event of receipt of 
amendments (Rule 48.2(h)) 
- upon request of the applicant, before the expiration of the 
time limit referred to in Article 2](2)(a) 
- with sequence listingpart of description (Rule 5.2(a))